articleThe Lancet OncologyDec 16, 2019Closed access

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

SLSagar LonialHCHans C. LeeABAshraf BadrosSTSuzanne TrudelAKAjay K. Nooka

Winship Cancer Institute · Emory University · +40 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

791
total citations
FWCI
69.27
Percentile
100%
References
31
Citations per year

Authors

38

Topics & keywords

Topics
Keywords
  • Medicine
  • Internal medicine
  • Refractory (planetary science)
  • Population
  • Multiple myeloma
  • Discontinuation
  • Toxicity
  • Phases of clinical research
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding